 Home > Active Ingredient News > Antitumor Therapy > JAMA Netw Open: The best initial treatment for advanced oropharyngeal squamous cell carcinoma?

JAMA Netw Open: The best initial treatment for advanced oropharyngeal squamous cell carcinoma?

 Last Update: 2021-06-10
 Source: Internet
 Author: User

Tags

low grade tumor

old journal cover

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Targeted radiotherapy and chemotherapy (Definitive chemoradiotherapy) and upfront surgical treatment (Upfront surgical treatment) are both considered to be the standard regimen for advanced oropharyngeal squamous cell carcinoma.

This study aims to compare the efficacy of targeted radiotherapy and chemotherapy and preoperative treatment for advanced oropharyngeal squamous cell carcinoma.

This is a retrospective comparative analysis of efficacy, including stage III or IV oropharyngeal squamous cell carcinoma diagnosed from 2007 to 2015 (excluding patients with T4b or N3 stage); from June 2019 to December 2020 Perform data analysis monthly.

A total of 1180 patients (89.

1180 patients in the targeted radiotherapy and chemotherapy group, 694 patients in the preoperative treatment group, 486 patients

Overall survival rate of the two groups of patients

The median follow-up was 3.

Median follow-up was 3.

Progression-free survival of the two groups of patients

The progression-free survival of the preoperative surgical treatment group was worse than that of the targeted radiotherapy and chemotherapy group (HR 1.

The progression-free survival of the preoperative surgical treatment group was worse than that of the targeted radiotherapy and chemotherapy group

Local recurrence-free survival of the two groups of patients

In summary, the results of this study show that after calibration based on prognostic-related baseline factors, the efficacy of targeted radiotherapy and chemotherapy can be comparable to that of previous surgical treatment.

All in all, in this study, the efficacy of targeted radiotherapy and chemotherapy and preoperative treatment in advanced oropharyngeal squamous cell carcinoma is still the same.

Original source:

Tsai Mu-Hung,Cheng Yung-Jen,Pao Tzu-Hui et al.

Modality for Treatment of Primary Association or Advanced Oropharyngeal Squamous the Cell-Journal of the Stage With Survival Outcomes, JAMA

in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Gemcitabine Base 95058-81-4

CAS No.: 95058-81-4

$1-1.2/MT EXW

Amoxicillin Diketopiperazine

CAS No.: 2088961-37-7

Pharmacy Grade

$1.3-1.5/G FOB

Pentostatin powder High quality 99% Herbal extract White Powder cas 53910-25-1

CAS No.: 53910-25-1

Chemical Grade

$4-5/UNIT FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.